EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates

Rajkumar Ravi iD, Selvakumar Karuthapandi iD

Beilstein Journal of Organic Chemistry · 09.03.2026 · 22 · 416-435

DOI: 10.3762/bjoc.22.29 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Beilstein Journal of Organic Chemistry, online erschienen am 09.03.2026. Verfasst von Rajkumar Ravi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Advanced Sciences, VIT-AP University, Amaravati-522237, Andhra Pradesh, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VIT University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The structure-based approach remains a valuable tool for rapid and high-throughput drug discovery and lead optimisation. In this study, we report the in-silico modelling and anticancer activity of two 1,8-napthalimide (NAP) derivatives containing organyl selanyl groups. The organylselanyl function n -octylselanyl ( n -OctSe) or phenylselanyl (PhSe) was introduced at the 6-position of a naphthalimide structure having a conserved 3-(4-( tert -butyl)phenoxy)propyl function at the imide nitrogen. The resultant naphthalimide–organylselanyl conjugates, NAP-SePh and NAP-Se( n -Oct), were characterised using various spectroscopic techniques, including FTIR, ¹H, ¹³C, ⁷⁷Se NMR and high-resolution mass spectrometry (HRMS). NAP-SePh was structurally characterised by single-crystal X-ray diffraction analysis. The anticancer potential of the NAP-SePh and NAP-Se( n -Oct) was evaluated using an in vitro cell viability assay with MDA-MB-231 triple-negative breast cancer (TNBC) cells. The IC₅₀ values for compounds NAP-SePh and NAP-Se( n -Oct) were 27.92 ± 3 µM and 23.06 ± 3 μM, respectively. Molecular docking simulations revealed that NAP-SePh and NAP-Se( n -Oct) show binding affinities of −10.39 and −8.53 kcal/mol for the (1M17) active, and −10.66 and −10.59 kcal/mol for the (4HJO) inactive conformation of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in which erlotinib, a well-known anticancer drug, binds.

Schlagwörter

Stichwörter der Autor:innen

MDA-MB-231cell line studydensity functional theorymolecular dockingorganoselanyl conjugates

Autor:innen und Institutionen

  • Department of Chemistry, School of Advanced Sciences, VIT-AP University, Amaravati-522237, Andhra Pradesh, India.

ORCID-Profile: Rajkumar Ravi, Selvakumar Karuthapandi

Förderung

  • VIT University

Zitieren

APA

Ravi, R., & Karuthapandi, S. (2026). Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates. Beilstein Journal of Organic Chemistry, 22, 416-435. https://doi.org/10.3762/bjoc.22.29

Vancouver

Ravi R, Karuthapandi S. Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates. Beilstein Journal of Organic Chemistry. 2026;22:416-435. doi:10.3762/bjoc.22.29

BibTeX
@article{Ravi2026,
  author = {Ravi, Rajkumar and Karuthapandi, Selvakumar},
  title = {Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates},
  journal = {Beilstein Journal of Organic Chemistry},
  year = {2026},
  volume = {22},
  pages = {416--435},
  doi = {10.3762/bjoc.22.29}
}
Kostenlos starten →